FindTrial
Sign In

Estimation of cost value based on the convenience of an anti-influenza agent baloxavir marboxil

Estimation of cost value based on the convenience of an anti-influenza agent baloxavir marboxil - Estimation of cost value based on the convenience of an anti-influenza agent baloxavir marboxil

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000041452
Enrollment
3000
Registered
2020-08-18
Start date
2020-08-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

influenza

Interventions

None listed

Sponsors

Shionogi & CO., LTD.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Individuals who were prescribed any influenza drugs (oral or inhalation) last season (from October 2018 to April 2019) or this season (from October 2019 to the present)

Exclusion criteria

Exclusion criteria: N/A

Design outcomes

Primary

MeasureTime frame
Convenience of drugs: route, frequency, and duration of administration, and out-of-pocket expenses—

Countries

Japan

Contacts

Public ContactAkira Yokomasu

Shionogi & CO., LTD. Medical Affairs Dept.

akira.yokomasu@shionogi.co.jp06-6485-5201

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026